Eledon Pharmaceuticals, Inc.

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart Tegoprubart granted Orphan Drug designation by the FDA for the prevention of allograft rejection in liver transplantation IRVINE, Calif. , March 19, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2025 operating and financial results and reviewed recent business highlights. “Over the past year, Eledon has made significant progress advancing tegoprubart, our anti-CD40L antibody, as a potential next-generation immunosuppressive therapy across multiple transplantation settings,” said David-Alexandre C. Gros , M.D., Chief Executive Officer of Eledon. “The over 100 patients treated across our transplantation programs to date provide a growing body of evidence that reinforces our conviction that tegoprubart can address key safety and efficacy issues with current standard-of-care transplant immunosuppression. Looking ahead, we anticipate multiple important milestones this year, including regulatory engagement to support advancement into Phase 3 development in kidney transplantation, initiation of an additional islet transplantation trial in type 1 diabetes, and the start of a clinical trial in liver transplantation.” Fourth Quarter 2025 and Recent Corporate Developments Announced that tegoprubart has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the prevention of allograft rejection in liver transplantation. Tegoprubart previously received Orphan Drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). Presented 24-month follow-up data from eight patients enrolled in the Phase 1b long-term extension trial evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium . The data continue to support the favorable safety and tolerability profile of tegoprubart with no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation reported during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months. Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart as the core immunosuppressant following islet transplantation in an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute . All 10 patients who were more than four weeks post-transplant achieved 100% insulin independence and a most recent hemoglobin A1C (HbA1c) below 6.0%, with a mean most recent HbA1c across the 10 patients of approximately 5.35%. Tegoprubart-based immunosuppression was generally well tolerated with reported post-transplant immunosuppression-related adverse events successfully treated by lowering the mycophenolic acid dose, if necessary. There were no rejection episodes, and no patients developed de novo donor-specific HLA antibodies. Additionally, no evidence of nephrotoxicity, hypertension or neurotoxicity, which are commonly associated with tacrolimus-based immunosuppression regimens, was observed. The study continues to generate significant patient demand with inquiries received from several hundred T1D patients. Anticipated Upcoming Milestones Receive FDA guidance on the Phase 3 trial design assessing tegoprubart in kidney transplantation, followed by initiation of the Phase 3 trial pending regulatory alignment. Report long-term data from Phase 1 and Phase 2 BESTOW studies evaluating tegoprubart in kidney transplantation. Receive FDA regulatory guidance on path to market for tegoprubart in islet cell transplantation and xenotransplantation. Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients with renal dysfunction receiving an islet cell transplant. Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo liver transplant. Initiate an investigator-led study evaluating tegoprubart for kidney transplant tolerance induction. Full Year 2025 Financial Results Research and development (R&D) expenses for the year ended December 31, 2025 were $66.3 million , including $4.2 million of non-cash stock-based compensation expense, compared to $52.0 million , including $4.3 million of non-cash stock-based compensation expense, for the comparable period in 2024. The increase was primarily driven by continued advancement of the tegoprubart clinical development programs, including expanded clinical trial activity and manufacturing scale-up, as well as increased personnel to support these efforts. General and administrative expenses for the year ended December 31, 2025 were $17.0 million , including $6.2 million of non-cash stock-based compensation expense, compared to $18.6 million , including $8.8 million of non-cash stock-based compensation expense, for the comparable period in 2024. The decrease was primarily driven by lower stock-based compensation expense, partially offset by higher professional services and personnel-related costs. Net loss for the year ended December 31, 2025 was $45.6 million , or $0.52 per basic share of common stock, compared to a net loss of $36.2 million , or $0.66 per basic share of common stock, for the comparable period in 2024. The 2025 net loss included a non-cash gain of $33.4 million from changes in the fair value of warrant liabilities, while the 2024 net loss included a non-cash gain of $30.9 million from such changes. Excluding the non-cash items related to changes in the fair value of warrant liabilities, Eledon would have recorded a net loss of $79.1 million for the year ended December 31, 2025 and $67.1 million for the year ended December 31, 2024 . About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals , Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com. Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to maintain proper and effective internal control over financial reporting and other risks disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our Annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Stephen Jasper Gilmartin Group (858) 525 2047stephen@gilmartinir.com Media Contact: Jenna Urban CG Life(212) 253 8881jurban@cglife.com Source: Eledon Pharmaceuticals Source: Eledon Pharmaceuticals, Inc.

Plus, news about Eledon, Sobi, Ovid and CytomX: 🗓️ Ionis updates prion disease study timelines: The California oligonucleotide powerhouse has pushed back the primary completion of its Phase 1/2a trial to February 2027, from an earlier goal of July 2025, according to an update to the US federal trials database. Ionis said in a letter to the prion disease community this week that it is adding a third dosing regimen, of about 20 additional patients, to the clinical trial, named PrProfile. “The decision to expand PrProfile is based on a review of interim data showing an encouraging safety and tolerability profile, and that ION717 is engaging with its target biology (i.e., prion protein),” Ionis wrote in the letter. Misfolded proteins lead to the fatal brain disease. Other biotechs such as Gate Bioscience are in this space. — Kyle LaHucik 📊 Arvinas says PROTAC reduced biomarker in Parkinson’s disease: In a Phase 1 study of Parkinson’s patients, the company’s program ARV-102 reduced LRRK2 levels in the cerebrospinal fluid by “approximately 50% or greater” after four weeks. Patients received one of three doses ranging from 20 mg to 80 mg. — Max Gelman 📊 Eledon shares more type 1 diabetes data: The biotech’s immunosuppressant candidate, tegoprubart, was given to 12 patients with diabetes undergoing an islet transplant in an investigator-sponsored trial. All ten patients who were four weeks post-transplant achieved insulin independence, and there were no cases of rejection. The data add to previous results reported in 2024. Eledon is also advancing tegoprubart for patients receiving a kidney transplant . — Ayisha Sharma 📊 Sobi to advance sepsis program following Phase 2a data: The Swedish company said high-dose emapalumab improved organ function in 60% of patients with interferon-gamma driven sepsis, versus 40% for standard of care plus placebo. But the trial, which enrolled 75 patients across three arms, was not powered for statistical significance, a Sobi spokesperson said in an email. The company is discussing a path forward with regulators. — Ayisha Sharma 💰 Ovid reports safety data, raises cash: The biotech’s 7 mg dose of OV329 showed “favourable safety and tolerability” in a Phase 1 study in healthy volunteers. Ovid plans to advance the candidate to a Phase 2 trial in focal onset seizures. The company is also raising $60 million in private placement to expand into two indications: tuberous sclerosis complex seizures and infantile spasms. — Ayisha Sharma 💰 CytomX prices $250M offering: The biotech will use the cash to fund its antibody-drug conjugate varsetatug masetecan, or Varseta-M. Earlier this week, CytomX read out late-line colorectal cancer data for Varseta-M, causing its stock price to rise by about 45%. — Max Gelman

The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026–2036), mainly attributed to the increasing prevalence of NMOSD, growing awareness, advancement in diagnostic techniques, and the launch of emerging therapies such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others, reports DelveInsight.. 预计在预测期（2026-2036年）内，7MM的视神经脊髓炎谱系障碍市场规模将呈现正增长，主要归因于NMOSD患病率的增加、意识的提高、诊断技术的进步以及新兴疗法的推出，如BAT4406F（百奥泰生物制药）、Telitacicept (RC18)（荣昌生物/Vor Bio）、Divozilimab (BCD-132)（Biocad）等，DelveInsight报告称。LAS VEGAS 拉斯维加斯, ，March 16, 2026 2026年3月16日/PRNewswire/ -- Recently published Neuromyelitis Optica Spectrum Disorder Market Insights report includes a comprehensive understanding of current treatment practices, neuromyelitis optica spectrum disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /PRNewswire/ -- 近期发布的视神经脊髓炎谱系障碍市场洞察报告包含对当前治疗实践、视神经脊髓炎谱系障碍新兴药物、各疗法的市场份额以及2022年至2036年当前和预测的市场规模的全面理解，细分市场包括主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）。Neuromyelitis Optica Spectrum Disorder Market Summary 视神经脊髓炎谱系障碍市场概况The total neuromyelitis optica spectrum disorder treatment market size is expected to grow positively by 2036 in the leading markets. 预计到2036年，主要市场中的视神经脊髓炎谱系疾病治疗市场规模将实现正增长。The United States accounted for the largest NMOSD treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 2025年，美国的NMOSD治疗市场规模最大，相比之下，其他主要市场（包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本）的规模较小。The prevalence among females was 女性中的患病率为9.48 per 100,000 每10万人中9.48人, while among males it was ，而男性中则是3.52 per 100,000 每10万人中3.52人. The study observed a female-to-male ratio of approximately 。研究观察到男女比例约为3.5:1 3.5:1for NMOSD. 用于NMOSD。Leading NMOSD companies, such as 领先的NMOSD公司，如Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, 百奥泰、荣昌生物、Vor Bio、Biocadand others, are developing new NMOSD treatment drugs that can be available in the NMOSD market in the coming years. 并且其他公司，正在开发新的NMOSD治疗药物，这些药物可能在未来几年内进入NMOSD市场。The promising NMOSD therapies in clinical trials include 临床试验中颇有前景的NMOSD疗法包括BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), BAT4406F，泰利西普（RC18），迪沃奇单抗（BCD-132），and others. 和其他人。Discover what is the current and projected global NMOSD market size @ 发现当前和预计的全球NMOSD市场规模 @https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-marketKey Factors Driving the Growth of the Neuromyelitis Optica Spectrum Disorder Market 推动视神经脊髓炎谱系障碍市场增长的关键因素Improved Diagnostic Capabilities: 改进的诊断能力：Advances in diagnostic tools, especially biomarker testing like AQP4-IgG and MOG-IgG assays, have significantly increased diagnostic accuracy and reduced delays in identifying NMOSD cases. 诊断工具的进步，特别是像AQP4-IgG和MOG-IgG检测这样的生物标志物测试，显著提高了诊断的准确性，并减少了识别NMOSD病例的延误。Expansion of Targeted Therapeutic Options: 靶向治疗选择的扩展： The launch and approval of novel biologic therapies, such as monoclonal antibodies and complement inhibitors, that specifically target immune pathways in NMOSD have transformed treatment approaches, driving higher adoption and market demand. 新型生物疗法（如单克隆抗体和补体抑制剂）的推出和获批，这些疗法专门靶向NMOSD中的免疫通路，已经改变了治疗方式，推动了更高的采用率和市场需求。Launch of Emerging NMOSD Drugs: 新型NMOSD药物的上市：The dynamics of the NMOSD market are expected to change in the coming years due to the launch of emerging therapies such as 由于新兴疗法的推出，预计未来几年NMOSD市场的动态将发生变化，例如BAT4406F BAT4406F(Bio-Thera Solutions), 百奥泰生物制药股份有限公司，Telitacicept (RC18) 泰它西普 (RC18)(RemeGen/Vor Bio), （荣昌生物/沃贝奥生物），Divozilimab (BCD-132) 迪沃齐利单抗 (BCD-132)(Biocad), and others. （Biocad）和其他公司。Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the current treatment strategies for NMOSD encompass a multidisciplinary approach aimed at managing symptoms and enhancing quality of life. While there is no cure for NMOSD, interventions such as immunosuppressive therapy play a crucial role in the management of NMOSD. 德尔菲洞察公司预测与分析高级顾问拉曼迪普·辛格表示，目前NMOSD的治疗策略包括旨在管理症状和提高生活质量的多学科方法。虽然NMOSD尚无治愈方法，但免疫抑制疗法等干预措施在NMOSD的管理中起着至关重要的作用。Recently approved therapies offer hope for future advancements in NMOSD treatment.. 最近获批的疗法为NMOSD治疗的未来发展带来了希望。Neuromyelitis Optica Spectrum Disorder Market Analysis 视神经脊髓炎谱系障碍市场分析Current management strategies for NMOSD provide effective symptom control but do not offer a cure. Acute relapses are typically addressed using high-dose intravenous corticosteroids, such as methylprednisolone. 当前针对NMOSD的管理策略能够有效控制症状，但无法治愈。急性复发通常使用高剂量静脉注射糖皮质激素（如甲泼尼龙）进行处理。Common long-term therapies include 常见的长期疗法包括corticosteroids, azathioprine, mycophenolate mofetil, and rituximab, with azathioprine or mycophenolate mofetil 皮质类固醇、硫唑嘌呤、霉酚酸酯和利妥昔单抗，使用硫唑嘌呤或霉酚酸酯often paired with low-dose steroids. For patients who do not respond adequately to intravenous corticosteroids during severe relapses, plasma exchange can be an effective alternative. 通常与低剂量类固醇联合使用。对于在严重复发期间对静脉注射皮质类固醇反应不佳的患者，血浆置换可以作为一种有效的替代方案。In July 2025, NHS England introduced a national commissioning policy that recommends and funds the use of 2025年7月，英国国家医疗服务体系（NHS）英格兰引入了一项国家委托政策，该政策建议并资助使用ACTEMRA (tocilizumab) 托珠单抗（ACTEMRA）for NMOSD patients who are unable to tolerate or have not responded to earlier treatments. 对于无法耐受或未对先前治疗产生反应的NMOSD患者。ACTEMRA is delivered through specialised neurology centres under NHS England. Although tocilizumab had previously been authorized by the MHRA for several inflammatory conditions, it had not been specifically approved for NMOSD in the UK until this policy. ACTEMRA 由 NHS England 的专业神经科中心提供。尽管 tocilizumab 之前已获得 MHRA 批准用于多种炎症性疾病，但在英国，直到这一政策出台前，它并未被特别批准用于 NMOSD。In the United States, FDA-approved treatments for NMOSD include 在美国，FDA批准的NMOSD治疗方法包括ENSPRYNG, ULTOMIRIS 安适平，优特敏, and others. ，以及其他。Additionally, emerging pipeline therapies, such as 此外，新兴的管道疗法，如BAT4406F BAT4406F(Bio-Thera Solutions), 百奥泰生物制药Telitacicept (RC18) 泰它西普 (RC18)(RemeGen/Vor Bio), （荣昌生物/沃贝奥生物），Divozilimab (BCD-132) 迪沃齐利单抗 (BCD-132)(Biocad), and others, are contributing to ongoing innovation in the NMOSD treatment landscape. （Biocad）等公司正在为NMOSD治疗领域的持续创新做出贡献。Neuromyelitis Optica Spectrum Disorder Competitive Landscape 视神经脊髓炎谱系障碍竞争格局Some of the NMOSD drugs under development include 一些正在开发的NMOSD药物包括BAT4406F BAT4406F(Bio-Thera Solutions), 百奥泰生物制药股份有限公司，Telitacicept (RC18) 泰乐赛普（RC18）(RemeGen/Vor Bio), （荣昌生物/沃贝奥生物），Divozilimab (BCD-132) 迪沃齐利单抗 (BCD-132)(Biocad), and others. （Biocad）和其他。Bio-Thera Solutions' BAT4406F 百奥泰生物的BAT4406Fis an investigational, Phase II glyco-engineered monoclonal antibody being studied in China. The treatment is designed to boost antibody-dependent cellular cytotoxicity (ADCC). As a type I anti-CD20 antibody, it promotes B-cell depletion through complement-dependent cytotoxicity while enhancing ADCC, and is currently under evaluation for autoimmune conditions such as NMOSD.. 是一种正在中国研究的二期临床试验中的糖工程改造单克隆抗体。该治疗旨在增强抗体依赖性细胞毒性（ADCC）。作为一种I型抗CD20抗体，它通过补体依赖性细胞毒性促进B细胞清除，同时增强ADCC，目前正被评估用于治疗如NMOSD等自身免疫性疾病。RemeGen/Vor Bio's Telitacicept (RC18) 荣昌生物/Vor Bio的泰勒他赛普（RC18）is an innovative fusion protein developed for the treatment of autoimmune disorders. It is composed of the extracellular domain of the human TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) receptor fused to the Fc portion of human IgG. Telitacicept is engineered to block two signaling molecules essential to B-cell maturation, BLyS and APRIL.. 是一种用于治疗自身免疫性疾病的创新融合蛋白。它由人TACI（跨膜激活剂和钙调制器及亲环素配体相互作用因子）受体的胞外域与人IgG的Fc部分融合而成。泰利西普旨在阻断对B细胞成熟至关重要的两个信号分子：BLyS和APRIL。Biocad's BCD-132 (divozilimab) 百欧卡的BCD-132（迪沃齐利单抗）is a monoclonal antibody and a novel investigational therapy being developed for multiple sclerosis and other autoimmune conditions. Monoclonal antibodies are laboratory-engineered proteins modeled on the natural antibodies produced by the immune system, each designed to bind specifically to a particular target in the body.. 是一种单克隆抗体，也是正在开发用于多发性硬化症和其他自身免疫性疾病的新型研究疗法。单克隆抗体是实验室设计的蛋白质，模仿免疫系统产生的天然抗体，每种抗体都旨在特异性结合身体中的特定目标。For BCD-132, the target is the CD20 protein found on B cells. When BCD-132 attaches to CD20, it triggers the elimination of these B cells, lowering their numbers and thereby reducing immune activity associated with autoimmune diseases. Divozilimab's safety and effectiveness have been evaluated in preclinical animal studies, and clinical trials in humans are currently ongoing.. 对于BCD-132，其靶点是B细胞上的CD20蛋白。当BCD-132附着于CD20时，会触发这些B细胞的清除，减少它们的数量，从而降低与自身免疫疾病相关的免疫活性。迪沃齐利单抗的安全性和有效性已在临床前动物研究中得到评估，目前针对人类的临床试验正在进行中。The anticipated launch of these emerging therapies are poised to transform the NMOSD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the NMOSD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期推出，有望在未来几年内改变NMOSD市场的格局。随着这些前沿疗法不断成熟并获得监管机构的批准，它们预计将重塑NMOSD市场，提供新的治疗标准，并为医疗创新和经济增长带来机遇。Discover more about are new drugs upcoming in NMOSD pipeline @ 了解更多关于NMOSD领域即将推出的新药信息 @Neuromyelitis Optica Spectrum Disorder Drugs 视神经脊髓炎谱系疾病药物What is Neuromyelitis Optica Spectrum Disorder? 什么是视神经脊髓炎谱系障碍？Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition in which the body's immune system mistakenly attacks the central nervous system, primarily targeting the optic nerves and spinal cord. This leads to episodes of optic neuritis, causing vision loss or eye pain, and transverse myelitis, which can result in limb weakness, sensory changes, or problems with bladder and bowel control. 视神经脊髓炎谱系障碍（NMOSD）是一种罕见的自身免疫性疾病，患者的免疫系统错误地攻击中枢神经系统，主要影响视神经和脊髓。这会导致视神经炎发作，引起视力丧失或眼痛，以及横贯性脊髓炎，可能导致肢体无力、感觉改变或膀胱和肠道控制问题。NMOSD is often associated with antibodies against a protein called aquaporin-4 (AQP4), which helps distinguish it from similar conditions like multiple sclerosis. Because attacks can be severe and cause lasting disability, early diagnosis and long-term treatment to prevent relapses are essential for managing the disorder effectively.. NMOSD 通常与针对一种名为水通道蛋白 4 (AQP4) 的蛋白质的抗体有关，这有助于将其与类似多发性硬化症的病症区分开来。由于发作可能很严重并导致长期残疾，因此早期诊断和长期治疗以预防复发对于有效管理该疾病至关重要。Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation 视神经脊髓炎谱系障碍流行病学细分The NMOSD epidemiology section provides insights into the historical and current NMOSD patient pool and forecasted trends for the leading markets. The diagnosed prevalence rate of NMOSD is estimated at nearly NMOSD流行病学部分提供了对历史和当前NMOSD患者群体的洞察，并预测了主要市场的趋势。NMOSD的诊断患病率估计接近1.5 per 100,000 每10万人中1.5人population. Between 人口。之间70–80% 70%-80%of NMOSD patients will have anti-AQP4 antibodies. NMOSD患者将具有抗AQP4抗体。The NMOSD treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: NMOSD治疗市场报告提供了2022年至2036年研究期间主要市场的流行病学分析，细分如下： Total Prevalent Cases of NMOSD NMOSD的总流行病例数Total Diagnosed Prevalent Cases of NMOSD NMOSD的总诊断患病数Gender-specific Diagnosed Prevalent Cases of NMOSD 性别特异的NMOSD确诊病例数Treated Cases of NMOSD NMOSD治疗病例Neuromyelitis Optica Spectrum Disorder Market Report Metrics 视神经脊髓炎谱系障碍市场报告指标Details 详细信息Study Period 学习期2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 7MM［美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本］。Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation 视神经脊髓炎谱系障碍流行病学细分Total Prevalent Cases of NMOSD, Total Diagnosed Prevalent Cases of NMOSD, Gender-specific Diagnosed Prevalent Cases of NMOSD, and Treated Cases of NMOSD NMOSD的总流行病例数、NMOSD的总确诊流行病例数、NMOSD的性别特定确诊流行病例数以及NMOSD的治疗病例数Key Neuromyelitis Optica Spectrum Disorder Companies 主要视神经脊髓炎谱系疾病公司Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, Genentech, Chugai Pharmaceuticals, AstraZeneca, Alexion, and others 百奥泰生物、荣昌生物、Vor Bio、Biocad、基因泰克、中外制药、阿斯利康、Alexion等公司Key Neuromyelitis Optica Spectrum Disorder Therapies 关键的视神经脊髓炎谱系疾病疗法 BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), ENSPRYNG, ULTOMIRIS, SOLIRIS, and others BAT4406F、泰利西普（RC18）、地沃单抗（BCD-132）、ENSPRYNG、ULTOMIRIS、SOLIRIS 等等Scope of the 范围Neuromyelitis Optica Spectrum Disorder 视神经脊髓炎谱系障碍Market Report 市场报告Therapeutic Assessment: 治疗评估：Neuromyelitis Optica Spectrum Disorder current marketed and emerging therapies 视神经脊髓炎谱系障碍当前市场上的和新兴的疗法Neuromyelitis Optica Spectrum Disorder 视神经脊髓炎谱系障碍Market Dynamics: 市场动态：Key Market Forecast Assumptions of Emerging Neuromyelitis Optica Spectrum Disorder Drugs and Market Outlook 新兴视神经脊髓炎谱系疾病药物的关键市场预测假设与市场展望Competitive Intelligence Analysis: 竞争情报分析：SWOT analysis and Market entry strategies SWOT分析与市场进入策略Unmet Needs, KOL's views, Analyst's views, Neuromyelitis Optica Spectrum Disorder Market Access and Reimbursement 未满足的需求、关键意见领袖的观点、分析师的观点、视神经脊髓炎谱系障碍市场准入和报销 Download the report to understand what market trends are shaping NMOSD over the next decade @ 下载报告以了解未来十年内影响NMOSD的市场趋势 @Neuromyelitis Optica Spectrum Disorder Market Analysis 视神经脊髓炎谱系障碍市场分析Table of Contents 目录1 1Neuromyelitis Optica Spectrum Disorder Market Key Insights 视神经脊髓炎谱系障碍市场关键洞察2 2Neuromyelitis Optica Spectrum Disorder Market Report Introduction 视神经脊髓炎谱系障碍市场报告介绍3 3NMOSD Market Overview at a Glance NMOSD市场概况一览 3.1 3.1Market Share (%) Distribution of NMOSD by Therapies in the 7MM in 2025 2025年7MM中NMOSD按疗法划分的市场份额（%）分布3.2 3.2Market Share (%) Distribution of NMOSD by Therapies in the 7MM in 2036 2036年七大市场NMOSD按疗法划分的市场份额（%）分布4 4Methodology 方法论5 5Executive Summary 执行摘要 6 6Key Events 关键事件7 7Disease Background and Overview: NMOSD 疾病背景与概述：NMOSD7.1 7.1Introduction 介绍7.2 7.2Classification 分类7.3 7.3Causes 原因7.4 7.4Signs and Symptoms 体征与症状7.5 7.5Pathophysiology 病理生理学7.6 7.6Clinical features 临床特征7.7 7.7Diagnosis 诊断7.8 7.8Treatment and Management 治疗与管理8 8Epidemiology and Patient Population of NMOSD in the 7MM 7MM中NMOSD的流行病学和患者人群8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale 假设与理由8.3 8.3Total Prevalent Cases of NMOSD in the 7MM 7MM中NMOSD的总流行病例数8.4 8.4Total Diagnosed Prevalent Cases of NMOSD in the 7MM 7MM中NMOSD的总诊断患病数8.5 8.5The US 美国8.5.1 8.5.1Total Prevalent Cases of NMOSD NMOSD的总流行病例数8.5.2 8.5.2Total Diagnosed Prevalent Cases of NMOSD NMOSD的总诊断患病数8.5.3 8.5.3Gender-specific Diagnosed Prevalent Cases of NMOSD 性别特异的NMOSD确诊病例数8.5.4 8.5.4Treated Cases of NMOSD NMOSD的治疗病例8.6 8.6EU4 and the UK EU4 和英国8.7 8.7Japan 日本9 9NMOSD Patient Journey NMOSD患者旅程10 10Marketed NMOSD Therapies 已上市的NMOSD疗法10.1 10.1Key Cross Competition 关键交叉竞争10.2 10.2 ENSPRYNG: Genentech/Chugai Pharmaceuticals ENSPRYNG：基因泰克/中外制药10.2.1 10.2.1Product Description 产品描述10.2.2 10.2.2Product Profile 产品概况10.2.3 10.2.3Other Developmental Activities 其他开发活动10.2.4 10.2.4 Clinical Trials Information 临床试验信息10.2.5 10.2.5Safety and Efficacy 安全性与有效性10.3 10.3ULTOMIRIS: AstraZeneca ULTOMIRIS：阿斯利康10.4 10.4SOLIRIS: Alexion/AstraZeneca SOLIRIS：Alexion/阿斯利康List to be continued in the final report. 最终报告中将继续列出清单。11 11Emerging NMOSD Therapies 新兴的NMOSD疗法11.1 11.1Key Cross Competition 关键交叉竞争11.2 11.2BAT4406F: Bio-Thera Solutions 百奥泰生物科技11.2.1 11.2.1Drug Description 药品说明书11.2.2 11.2.2Product Profile 产品概况11.2.3 11.2.3Other Developmental Activities 其他开发活动11.2.4 11.2.4 Clinical Trials Information 临床试验信息11.2.5 11.2.5Safety and Efficacy 安全性与有效性11.3 11.3Telitacicept (RC18): RemeGen/Vor Bio 泰利西普 (RC18): 荣昌生物/Vor BioList to be continued in the final report. 清单将在最终报告中继续。12 12NMOSD: Market Analysis NMOSD：市场分析 12.1 12.1Key Findings 主要发现12.2 12.2Key Neuromyelitis Optica Spectrum Disorder Market Forecast Assumptions 关键的视神经脊髓炎谱系障碍市场预测假设12.3 12.3Neuromyelitis Optica Spectrum Disorder Market Outlook 视神经脊髓炎谱系疾病市场展望12.4 12.4Conjoint Analysis 联合分析12.5 12.5Total Market Size of NMOSD in the 7MM 7MM中NMOSD的总市场规模12.6 12.6Market Size of NMOSD by Therapies in the 7MM 七大市场中NMOSD按疗法划分的市场规模 12.7 12.7The US Neuromyelitis Optica Spectrum Disorder Market 美国视神经脊髓炎谱系障碍市场12.8.1 12.8.1Total Market Size of NMOSD NMOSD总市场容量12.8.2 12.8.2Market size of NMOSD by Therapies 按疗法划分的NMOSD市场规模12.8 12.8EU4 and the UK Neuromyelitis Optica Spectrum Disorder Market 欧盟四国和英国视神经脊髓炎谱系疾病市场12.9 12.9Japan Neuromyelitis Optica Spectrum Disorder Market 日本视神经脊髓炎谱系障碍市场12.9.1 12.9.1Total Market Size of NMOSD NMOSD总市场容量12.9.2 12.9.2Market size of NMOSD by Therapies 按疗法划分的NMOSD市场规模13 13Key Opinion Leaders' Views on NMOSD 关键意见领袖对NMOSD的看法14 14NMOSD Market SWOT Analysis NMOSD市场SWOT分析15 15NMOSD Market Unmet needs NMOSD市场未满足的需求16 16Market Access and Reimbursement 市场准入与报销16.1 16.1The US 美国16.2 16.2In EU4 and the UK 在欧盟4国和英国16.3 16.3Japan 日本17 17Acronyms and Abbreviations 缩略语和简称18 18Bibliography 参考文献19 19Neuromyelitis Optica Spectrum Disorder Market Report Methodology 视神经脊髓炎谱系障碍市场报告方法论Related Reports 相关报告Neuromyelitis Optica Spectrum Disorder Clinical Trial Analysis 视神经脊髓炎谱系疾病临床试验分析Neuromyelitis Optica Spectrum Disorder 视神经脊髓炎谱系障碍Pipeline Insight 管道洞察– –2026 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NMOSD companies, including 报告全面洞察了研发管线的格局、管线药物概况（包括临床和非临床阶段产品）以及主要的NMOSD公司，包括Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Xiniao Biotech Co., Ltd. 百奥泰生物，百锐实验室，南京博恒生物技术有限公司，南京艾索生物治疗，上海交联药物研发有限公司，上海欣翱生物科技有限公司。, ，and others. 和其他人。Multiple Sclerosis 多发性硬化症Market 市场Multiple Sclerosis 多发性硬化症Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学和市场预测– –2034 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies including 报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场壁垒和多家多发性硬化症公司，包括Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma 诺华、赛诺菲、AB Science、罗氏、Clene纳米医学、InnoCare制药, ，and others. 和其他人。Relapsing-Remitting Multiple Sclerosis 复发-缓解型多发性硬化症Market 市场Relapsing-Remitting Multiple Sclerosis 复发缓解型多发性硬化症Market Insights, Epidemiology, and Market Forecast – 2034 市场洞察、流行病学和市场预测 - 2034report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key RRMS companies including 报告深入理解了该疾病、历史和预测的流行病学、个别疗法的市场份额，以及包括关键的复发缓解型多发性硬化症（RRMS）公司在内的信息。Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, Mapi制药、Apimeds、基因泰克（罗氏）、默克、Clene纳米医学、InnoCare制药、Oryzon基因组学、and others. 和其他人。CD40/CD40L Inhibitors CD40/CD40L抑制剂 Market 市场CD40/CD40L Inhibitors CD40/CD40L抑制剂 Market, Target Population, Competitive Landscape, and Market Forecast 市场、目标人群、竞争格局和市场预测– –2034 2034report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CD40/CD40L inhibitors companies including 报告深入介绍了市场趋势、市场驱动因素、市场障碍以及包括关键CD40/CD40L抑制剂公司在内的相关信息。Sanofi, UCB, Amgen, Eledon Pharmaceuticals, Kiniksa Pharmaceuticals, Memgen 赛诺菲、优时比、安进、埃莱登制药、金尼萨制药、梅根生物, ，and others. 和其他人。About 关于DelveInsight 德莱夫洞察DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. 德尔维洞察是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来支持制药公司以提高其业绩。通过我们的订阅平台PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur Shruti Thakur[emailprotected] 电子邮件地址+14699457679 +14699457679www.delveinsight.com www.delveinsight.comLogo: 标志：https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpgSOURCE DelveInsight Business Research, LLP 来源：DelveInsight商业研究有限公司21 21% %more press release views with 更多新闻发布观点 Request a Demo 请求演示